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Development of systemic treatment for advanced pancreatic cancer (APC) has been challenging. After fluorouracil, gemcitabine
(GEM) became the treatment of choice based on its benefit of symptom relief. Many cytotoxic agents have been combined with
GEM in search of regimens with improved survival benefit. However, there were only marginal benefits in people with good perfor-
mance status. Recently, the combination regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX)
was found to achieve unprecedented survival benefit and has become the preferred option for patients with good clinical
conditions. On the other hand, many biological agents have been combined with GEM, but only erlotinib was found to derive
statistically significant survival advantage. However, the eﬀect was too small to be appreciated clinically. The eﬀort in development
of targeted therapy in APC continues. This paper summarized key findings in the development of chemotherapy and targeted
therapy for APC patients and discussed future directions in management.
1. Introduction
Advanced pancreatic cancer (APC) is a dismal human cancer
withmedian overall survival ofmerely 6months. Approaches
such as radiation, conventional chemotherapy, or combina-
tion of these modalities could not alter the disease course.
Previously, fluorouracil (5FU) was given for treatment [1],
but it was later taken over by gemcitabine (GEM) due to its
eﬀect on alleviation of disease-related symptoms [2]. How-
ever, the survival benefit of GEM was small. In desperate
need of better treatment, much eﬀort has been put on explor-
ing new treatment regimes. It was once expected that bio-
logical agents could bring hope to this deadly cancer just like
how they revolutionized the treatment of many other malig-
nancies. When most of these agents seemed to fail,
a nongemcitabine-containing combination chemotherapy
(FOLFIRINOX) was found to give major improvement in
response and survival and set the new standard of the treat-
ment [3].
This paper summarized key development in the treat-
ment of APC and discussed future possibilities in light of our
current understanding.
2. Traditional Chemotherapy
The progress in the development of systemic treatment of
advanced pancreatic cancer (APC) has been slow (Figure 1).
Traditionally, fluorouracil (5FU) was the only treatment
option and provided only marginal benefit [1]. In 1997, Bur-
ris et al. in a randomized phase III trial showed that GEMwas
superior to 5FU in alleviation of disease-related symptoms
and improving survival [2]. Although the improvement of
median survival was merely 1.2 months (from 4.4 months
with 5FU to 5.6 months with GEM, P = 0.0025), the 1-year
survival rate was 18% for the GEM and 2% for the 5FU arms,
respectively. GEM also gave a favorable clinical benefit rate
(23.8% versus 4.8%, P = 0.0022). Thereafter, GEM took over
to become the standard treatment of APC.
Much eﬀort was directed to improve the outcome of
GEM treatment. GEM-based doublets with either platinum
analogues or 5FU were extensively studied (Table 1). When
GEM was combined with either cisplatin [4] or oxaliplatin
[5] in individual trials, no benefits over single-agent GEM
could be shown. Nevertheless, pooled analysis of these two
European trials [4, 5] demonstrated that GEM-platinum
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Figure 1: Selected signaling pathways and their targeting in advanced pancreatic cancer.
doublet gave a 25% reduction in risk of progression (P =
0.0030) and 19% reduction in risk of death (P = 0.031) [6].
Yet, these benefits were mainly observed in asymptomatic
patients with good performance status. On the other hand,
addition of 5FU to GEM did not yield any survival improve-
ment [7, 8]. This finding was further supported by trials
where 5FU was substituted by the prodrug capecitabine
(CAP) in the GEM doublet [9–11]. In these randomized
studies, the GEM-CAP combination improved neither the
progression-free survival (PFS), overall survival (OS), nor
quality of life (Table 1).
As APC is not the most prevalent cancer and most
clinical trials contained around 200–300 subjects, it has been
criticized that individual study has insuﬃcient statistical
power to detect the eﬀect of combination chemotherapy.
In view of this, a number of metaanalyses have been con-
ducted (see Table 2). In summary, they primarily showed
a significant benefit whenGEMwas combined with platinum
or 5FU, but not with other cytotoxic agents. The maximum
survival benefit of GEM-based combination chemotherapy
was only marginal and mainly derived from patients with
good performance status. Thus, the addition of platinum
analogues to GEM was not recommended in general.
Recently, in the French PRODIDGE 4/ACCORD 11 trial,
the polychemotherapy regimen FOLFIRINOX (oxaliplatin,
irinotecan, fluorouracil, and leucovorin) significantly
improved the median OS of metastatic pancreatic cancer
patients from 6.8 to 11.1 months when compared with
single-agent GEM [3]. Such a magnitude of median OS
improvement (4.3 months) was impressive but came with a
price. Notably, 45% of the enrolled patients reported grade 3
or 4 adverse events (AEs). The most common AEs were
diarrhea, fatigue, and vomiting. About 45% of patients
experienced grade 3/4 neutropenia, including febrile neutro-
penia in 5.4%. In view of significant treatment-related toxi-
cities, FOLFIRINOX is only recommended for patients with
good performance status and medical conditions.
3. Biological Therapy in Pancreatic Cancer
Pancreatic cancer is a heterogeneous disease. Although the
constitutively active K-rasG12D allele mutation has been
reported in 70%–90% of pancreatic cancers [15–17], no
single oncogene addiction driving the growth of this cancer
has been identified so far. According to the pancreatic cancer
genome project, this cancer contains at least 63 genetic alter-
ations on average. Besides K-ras, commonmutations include
FRAF (20%), AKT2 (20%), p16/CDKN2A (75%–80%), p53
(50%–75%), SMAD4 (50%–60%), and BRCA2 (10%) [17].
A number of cellular signaling pathways have been impli-
cated in the pathogenesis and maintenance of this cancer,
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Table 1: Major phase III GEM-based combination chemotherapy.
Regime No. pts ORR (%) PFS/TTP (mo) OS (mo) Reference
GEM + cisplatin 195 10.2 5.3 7.5 Heinemann et al. [4]
GEM 8.2 3.1 6.0
GEM + oxaliplatin 832 (P = 0.11) 2.7 5.7
Poplin et al. [5]
GEM 2.6 4.9
GEM + 5FU 322 6.9 3.4∗ 6.7 Berlin et al. [7]
GEM 5.6 2.2 5.4 ∗P = 0.022
GEM + capecitabine 533 19.2 5.3 7.1 Cunningham et al. [9]
GEM 12.4 3.8 6.2
GEM + capecitabine
GEM
319 QoL same n/a n/a Bernhard et al. [10]
GEM + capecitabine 319 10.0 4.3 8.4 (10.1∗) Herrmann et al. [11]
GEM 7.8 3.9 7.2 (7.4) (∗KPS 90–100; P = 0.014)
Abbreviation: ORR: overall response rate; PFS: progression free survival; TTP: time to progression; OS: overall survival; QoL: quality of life.
Table 2: Selected metaanalysis of GEM-based combination chemotherapy.
Reference No. of pts HR (all) HR for platinum HR for 5FU/capecitabine HR for other agents
Heinemann et al. [12] 4465 0.91∗ 0.85 0.9 0.99
Sultana et al. [13] 9970 0.91 — — —
Vaccaro et al. [14] 2422 0.87
0.94 (cisplatin, P = 0.61)
0.86 (P = 0.04) —
0.86 (oxaliplatin, P = 0.04)
∗ECOG PS 0-1: HR 0.76, P < 0.001; ECOG PS 2: HR 1.08, P = 0.40.
Abbreviations: HR: hazard ratio; 5FU: fluorouracil.
including hedgehog signaling, K-ras signaling, and trans-
forming growth factor beta (TGF-β) signaling, to name a few.
The following sections will discuss the key findings in the
quest of better treatment of APC using biological therapy.
3.1. Ras Signaling. As K-ras mutation is the commonest
mutation in pancreatic cancer, it was one of the earliest tar-
gets for drug development. The functional sites of this pro-
tein are diﬃcult to access, so scientists have attempted to tar-
get the enzyme taking part in modification/activation of Ras
called farnesyltransferase. Examples of farnesyltransferase
inhibitors (FTIs) include tipifarnib and SCH66336. These
agents as single agents or when combined with GEM showed
no appreciable activity in clinical trials [18–21], and the fail-
ure of FTIs was suspected to be due to recruitment of alter-
native pathways for Ras activation. Nowadays, people are still
developing novel methods such as antisense and RNA inter-
ference and inhibitors of its key eﬀector MEK kinase to target
the Ras protein or its signaling.
3.2. Epidermal Growth Factor Receptor (EGFR). EGFR is
overexpressed in human pancreatic cancer and is suspected
to play an important role in metastasis [22]. Both small
molecule tyrosine kinase inhibitors (TKIs) and monoclonal
antibodies are well-known strategies in targeting the EGFRs.
Erlotinib is a TKI of this class and has gained attention in the
treatment of APC. In the PA.3 study, which is a multicentre,
randomized, double-blind, and placebo-controlled clinical
study of erlotinib in combination with GEM in APC, the
erlotinib-GEM combination compared with single-agent
GEM showed a statistically improvement in PFS (HR 0.77
(95% CI, 0.64 to 0.92; P = 0.004)) and 1-year survival
(23% versus 17%; P = 0.023) [23]. The median OS was also
increased, but the improvement was small (6.24 versus 5.91
months, HR 0.82 (95% CI, 0.69 to 0.99; P = 0.038)). This
combination is not considered a clinically meaningful option
or a cost-eﬀective choice by many physicians.
Cetuximab is a chimeric monoclonal antibody against
ErbB-1 receptors with high specificity.
In a phase II study combining cetuximab and GEM in
untreated APC patients, there appeared to be encouraging
results [24]. But this combination did not show superiority
to single-agent GEM when tested in a randomized phase III
study (6.3 versus 5.9 months, HR 1.06; (95% CI, 0.91 to
1.23; P = 0.23)) [25]. In order to “intensify” the anti-EGFR
activity, people have attempted to combine another anti-
EGFR antibody, panitumumab, with erlotinib and GEM
[26]. Nevertheless, excessive toxicities shown in the phase II
study precluded further pursuit using this combination.
These research studies suggest that EGFR expression, though
correlating with tumor aggressiveness, does not necessarily
predict response to anti-EGFR therapy. The role of this class
of treatment remains to be defined.
3.3. Angiogenesis. Tumor growth is sustained by angiogen-
esis. Vascular endothelial growth factor (VEGF) expression
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was found to be associated with liver metastasis and poor
prognosis in pancreatic cancer [27]. However, trials on anti-
VEGF therapy in APC have been disappointing.
Bevacizumab is the most widely used anti-VEGF anti-
body and has been shown to enhance the eﬀect of chemo-
therapy in many other cancers. In the Cancer and Leukemia
Group B (CALGB) 80303 trial, patients with APC were ran-
domized to receive GEM with or without bevacizumab [28].
The addition of bevacizumab, however, did not extend over-
all survival. Similarly, in the phase III AVITA trial, patients
were given GEM with erlotinib plus either bevacizumab or
placebo. Despite improved PFS (median: 4.6 months versus
3.6 months, HR 0.73, P = 0.0002), it did not translate into
improved overall survival [29]. Attempts of other oral
inhibitors of VEGF receptor, such as axitinib [30] or afliber-
cept [31], or multikinase inhibitor like sorafenib [32], also
failed to improve survival.
3.4. Other Potential Treatment Strategies in the Near Future.
The chemotherapy-resistant nature of APC and failure of
antiangiogenesis therapy have prompted revision on the
existing model of tumor microarchitecture. Increasing evi-
dence suggests that pancreatic cancer is characterized by
“tumor desmoplasia,” the presence of dense stromal tis-
sue with decreased vascular density that penetrates and
envelopes the tumor [33]. It is now believed that this stromal
tissue impairs drug delivery, leading to treatment resistance.
nab-paclitaxel is an albumin-bound formulation of paclitaxel
with enhanced aﬃnity to a stromal protein called secreted
protein acidic and rich in cysteine (SPARC), which is over-
expressed in the stroma of APC. As a result, nab-paclitaxel is
concentrated around the tumor. Early phase I/II trial demon-
strated promising result when nab-paclitaxel was combined
with GEM in untreated APC patients. The reported res-
ponse rate was 48%, 1-year overall survival rate was 48%,
and the median OS was 12.2 months [34]. Phase III trial of
this combination is underway. Novel technological advance
such as nanotechnology might help develop drug therapy
that can overcome the barrier imposed by the dense stromal
microenvironment. Other ongoing pieces of research aiming
at manipulating the signaling or function of microenvi-
ronment include hedgehog pathway inhibitors and hyalu-
ronidase which breaks down the hyaluronan in the extracel-
lular matrix.
Pancreatic cancer is a complicated disease. Increasing
understanding of the molecular pathways to pathogenesis
and growth of pancreatic cancer showed that a number of
other signaling pathways are also implicated. For instance,
insulin-like growth factor receptor (IGFR-1) mRNA in pan-
creatic cancer was more than 30 times that in normal pan-
creatic tissue, and abnormal regulation of IGF-1 autocrine
loop was associated with increased tumorigenicity [35, 36].
Another signaling pathway, transforming growth factor beta
(TGF-β), has both the eﬀects of regulation of cell growth
and mediation of cancer cell proliferation and metastasis
[37]. Drug development that targets these pathways is still
preliminary.
In the era of personalized medicine, there is an unmet
need for development of biomarkers to guide management.
Carbohydrate antigen 19.9 (CA 19.9) is a widely accepted
surrogate marker for treatment response, although it has
only modest sensitivity and specificity [38]. Furthermore, K-
ras wild type status appeared to derive better survival from
erlotinib than K-ras mutant tumor, and so did patients who
developed rash during erlotinib treatment. Pharmacogenet-
ics also plays a role. Depressed level of GEMmetabolism gene
products such as deoxycytidine kinase (dCK) and ribonu-
cleoside reductases M1 and M2 (RRM1, RRM2) has been
correlated with treatment resistance to GEM [39–41]. Low
expressers of the nucleoside transporter-1 (hENT1) reduced
uptake of GEM in cell and were found to have poorer prog-
nosis [40]. In the future, we wish to identify biomarker that
can predict response of treatment and stratify patients
accordingly to enhance the treatment eﬀect.
4. Conclusion
The development of treatment for APC has been challenging.
Although many biological agents were tested, recent
advances in clinically significant treatment are dominated
by chemotherapy. The FOLFIRINOX regimen has gained
increased acceptance, and the eﬀect of nab-paclitaxel-GEM
combination is awaited from phase III study. The future
prospective depends on further understanding in the tumor
biology, targeting various growth factor signaling pathways,
and development of new technologies, including identifica-
tion of biomarkers that predict treatment response.
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